Dyskinesia is a major side effect of chronic levodopa (L-DOPA) administration, the reference treatment for Parkinson's disease (PD). High-frequency stimulation of the subthalamic nucleus (STN-HFS) alleviates parkinsonian motor symptoms and indirectly improves dyskinesia by decreasing L-DOPA requirement. However, inadequate stimulation can also trigger dyskinetic movements in PD patients and animal models. Here, we investigated the possible association between L-DOPA-and STN-HFS-induced dyskinesia and regulation of the NR2B subunit of NMDA receptors in the rodent model of PD. We subjected 6-OHDA-lesioned rats to HFS for 1 h, at an intensity triggering forelimb dyskinesia. Other 6-OHDA-lesioned rats were treated with chronic high doses of L-DOPA for ten days, to induce abnormal involuntary movements. The 6-OHDA lesion regulated NR2B only in the SNr, where the activation of NR2B was observed (as assessed by phosphorylation of the Tyr 1472 residue). Both STN-HFS and L-DOPA dyskinesiogenic treatments induced NR2B activation in the STN and EP, but only L-DOPA triggered NR2B hyperphosphorylation in the striatum. Finally, the use of CP-101,606 exacerbated L-DOPA-induced motor behavior and associated NR2B hyperphosphorylation in the striatum, STN and EP. Thus, NR2B activation in basal ganglia structures is correlated with dyskinesia.
Introduction
Levodopa (L-DOPA) administration remains the best treatment for alleviating the motor symptoms of Parkinson's disease (PD) (Birkmayer and Hornykiewicz, 1961) . However, its long-term use is associated with motor fluctuations and L-DOPA-induced dyskinesia (LID; Barbeau, 1969; Rascol and Fabre, 2001; Ahlskog and Muenter, 2001 ). High-frequency stimulation of the subthalamic nucleus (STN-HFS) indirectly improves LID in parkinsonian patients, essentially by decreasing the dose of L-DOPA required (Krack et al., 1999 (Krack et al., , 2003 Toda et al., 2004) . However, STN-HFS may also have prodyskinetic effects in PD patients (Limousin et al., 1996; Moro et al., 2002) and animal models of PD (Beurrier et al., 1997; Salin et al., 2002; Boulet et al., 2006) . Models of stimulation-induced dyskinesia have been used to improve our understanding of the mechanisms of STN-HFS and the physiopathology of dyskinesia. Unlike LID, the dyskinetic movements induced by HFS are transient, consistent with the occurrence of rapid adaptive mechanisms, with glutamate receptors potentially involved in this plastic response (Sgambato-Faure and Cenci, 2012).
For many years, N-methyl-D-aspartate (NMDA) glutamatergic receptors have been the most popular target for the development of antidyskinetic drugs (Chase and Oh, 2000) , such as amantadine, a weak non-competitive NMDA receptor antagonist that reduces dyskinesia in PD patients (Del Dotto et al., 2001 ) and animal models (Bibianni et al., 2005; Dekundy et al., 2007) . Several studies have highlighted a possible role for the NR2B subunit of the NMDA receptor in dyskinesia in PD patients (Calon et al., 2003) or parkinsonian animals (Calon et al., 2002; Oh et al., 1998; Chase and Oh, 2000; Dunah et al., 2000; Hurley et al., 2005) . The NR2B-selective antagonist CP-101,606 was shown to decrease peak-dose LID in a small proof-of-principle study in PD patients (Nutt et al., 2008) . We have also shown that the forelimb dyskinesia induced by STN-HFS in the normal rat is linked to NR2B hyperphosphorylation and attenuated by CP-101,606 (Quintana et al., 2010) . In this study, we aimed to extend this previous work by
